Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 1

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 2(3)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04911907Phase 2Unknown

Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors

Role: collaborator

NCT03906565Phase 2Suspended

Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer

Role: collaborator

NCT05052437Phase 1Completed

PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer

Role: collaborator

NCT03693547Phase 2Completed

Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）

Role: collaborator

NCT05172518Phase 3Not Yet Recruiting

Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

Role: collaborator

All 5 trials loaded